NeuroTherapeutics Pharma Receives Investment From The Epilepsy Therapy Project

Main Category: Epilepsy
Article Date: 11 Nov 2009 - 6:00 PDT

email to a friend   printer friendly   opinions  

NeuroTherapeutics Pharma, Inc., or NTP, a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, today announced that it received a $100,000 investment from the Epilepsy Therapy Project.

The Epilepsy Therapy Project invests in promising research efforts in order to help make new therapies a reality for patients, and the investment in NTP is one of the largest made in its history. "Our Board and our scientific advisors are enthusiastic about NTP and its lead compound. We view NTP's development effort as a potentially important new therapy with a novel mechanism of action for millions of people living with uncontrolled epilepsy," said Warren Lammert, Chairman and Co-Founder of the Epilepsy Therapy Project and epilepsy.com.

"We are honored that the Epilepsy Therapy Project has made such a substantial investment in our technology in order to help bring this new class of therapy to people with epilepsy, their families and clinicians. The Epilepsy Therapy Project's Board of Directors and Scientific Advisory Board are comprised of some of the most influential thought leaders in the space who have dedicated their lives to developing new therapies in this area of significant unmet need. We greatly appreciate their support and are honored to receive such an endorsement of our work," said Dr. Stephen D. Collins, Chief Executive Officer of NeuroTherapeutics Pharma.

About NeuroTherapeutics Pharma

NeuroTherapeutics Pharma is a privately held life sciences company which is focused on the discovery and development of novel therapeutics for patients suffering from CNS disorders. NTP will file an IND for its lead compound, NTP-2014, in the first quarter of 2010. The compound has exhibited excellent efficacy results in multiple models of epilepsy, chronic neuropathic pain and acute pain. NTP-2014 also has demonstrated a very favorable safety profile in the IND-enabling (GLP) subchronic toxicology studies.

NTP is financially backed by Novo Ventures and Thomas, McNerney and Partners. The company is led by a strong management team with significant drug development experience in the CNS space. Collectively, the team has filed over 15 INDs and has obtained approval for eight NDAs. The company is currently raising its Series B financing, which will advance NTP-2014 through multiple proof-of-concept Phase II trials and further develop a pipeline to expand this new class of therapy. Additional information can be found at the company's website: http://www.ntprx.com.

Source
Epilepsy Therapy Project

• Additional
• References
• Citations